Friday 15 March 2013

New monoclonal antibody may boost cancer therapy

Researchers at the Memorial Sloan-Kettering Cancer Centre in New York have developed a new monoclonal antibody capable of targeting proteins inside cancer cells. Known as ESK1, this monoclonal antibody targets a protein (WT1) associated with many types of cancer. According to Dr. David Scheinberg, inventor of ESK1, research has shown that a monoclonal antibody can be used "to recognize a cancer-associated protein inside a cell, and it will destroy the cell."

To read more about this study, click here.

Study mentioned: Dao T, et al. Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. Sci Transl Med. 2013 Mar 13;5(176)176ra33. PMID: 23486779

No comments:

Post a Comment